

**An exploration of the diagnostic journey of children with  
Neuronal Ceroid Lipofuscinosis (NCL).**

Alanna Gayko BSocSc (UON, Armidale) BN, MEd (SCU, Lismore)

A thesis submitted in fulfilment of the requirements for the degree of  
Master of Philosophy (Nursing)

September 2020

This research was supported by an Australian Government  
Research Training Program (RTP) Scholarship

## Statement of originality

I hereby certify that the work embodied in the thesis is my own work, conducted under normal supervision. The thesis contains no material which has been accepted, or is being examined, for the award of any other degree or diploma in any university or other tertiary institution and, to the best of my knowledge and belief, contains no material previously published or written by another person, except where due reference has been made. I give consent to the final version of my thesis being made available worldwide when deposited in the University's Digital Repository, subject to the provisions of the Copyright Act 1968 and any approved embargo.

Alanna Gayko

## Acknowledgements

This master's research thesis is a culmination of five years' work that would not have been possible without the expertise, support, and patience of my three supervisors. A special mention to my primary supervisor Professor Vanessa McDonald who has supported me throughout this degree to maintain a high standard of professionalism preparing and undertaking this research. The paediatric and rare disease experience that Dr Elizabeth Kepreotes has brought to our team has provided great insight into this study. Dr Tracy Dudding-Byth has contributed her genetic and rare disease expertise from a genetist's vantage. This is not an understatement, but this study would probably have not been possible without each individual in our team contributing their unique experience and perspective to this research.

A special mention to Associate Professor Kerry Inder who has always supported me through each stage from confirmation, ethics, and managerial guidance during this research. I also acknowledge the School of Nursing and Midwifery for the professional and administrative support I have received throughout my candidature. The Faculty of Health and Medicine Chief Librarian Debbie Booth has always been helpful when I have lost my Endnote library and prevented many tears. Thanks to Chris Oldmeadow and Jack Faulkner at Hunter Medical Research Institute, Newcastle for their statistical analysis of the study. This is also to acknowledge the other post-graduate students I have shared our journey during the past five years, especially Mieko Omura.

I would like to acknowledge the professional and personal support I have received from Professor Teresa Stone and Scott Davis. Also my thanks to Mark Kepreotes for providing his review of the grammar and spelling throughout my literature review. The formatting assistance of my graphics by James Vickers from Oversight Editing is acknowledged. I would also like to thank my mother Joy Hanrahan, and my father Peter Toohey for their personal support. My nursing friend of over forty years Jenny Ryder reviewed a late thesis draft. This thesis would not have been completed without my close circle of friends who have encouraged and cared for me, prompting me to keep going during particularly tough times. I have particularly appreciated the personal encouragement of the Shennan family during the last year of my studies.

The assistance of Lysosomal Diseases New Zealand and Genetics Alliance Australia for advertising the study is acknowledged. This research would not have proceeded without the support of the families affected by Batten disease in Australia and New Zealand, and the Australian chapter of Batten Disease Support and Research Association. These families have provided their personal insight of their children's diagnosis of this rare life-limiting disease. They have revealed a small window into their lives regarding diagnosis and left us with a greater understanding and respect for their personal circumstances. I have truly been humbled by the experience.

In memory of my fiancée Paul 'Swog' Schwager, and my sister Jacqueline Toohey.

## Abbreviations

ad	autosomal dominant
AD	Alzheimer disease
ADHD	attention deficit hyperactivity disorder
AFI	amaurotic familial idiocies
AFSM	auto-fluorescent storage material
ALP	Autosomal-Lysosomal pathway
ALS	Amyotrophic Lateral Sclerosis
ANCL	adult neuronal ceroid lipofuscinosis
A&NZ	Australian and New Zealand
ASD	autism spectrum disorder
ATP	adenosine 5-triphosphate
AVV	adeno-associated virus
BARN	Batten Animal Research Network
BBB	blood brain barrier
BD	Batten disease
BDSRA	Batten Disease Support and Research Association
BDSRAA	Batten Disease Support and Research Association (Australia)
CF	Cystic Fibrosis
CI	chief investigator
CLN	<i>ceroid lipofuscinosis neuronal (gene)</i>
CLN	ceroid lipofuscinosis neuronal (disease)
CLN7	<i>large major facilitator superfamily (MFS) or MFSD8</i>
CLP	curvilinear profiles
CNS	central nervous system
CReDITSS	Clinical Research Design and Statistics
CTSF: (CLN13)	<i>cathepsin F (CTSF)</i>
DNAJC5: (CLN4)	Adult autosomal dominant Parry disease: <i>subfamily C member</i>
DNA	Deoxyribonucleic acid
Dx	diagnosis
DBS	dried blood spot
DMD	Duchenne Muscular Dystrophy
EEG	electroencephalogram
EM	electron microscopy
ERG	electroretinogram
ERT	Enzyme Replacement Therapy
EU	European Union
FDA	Food and Drug Administration
FPP	fingerprint profiles
FTLD	Fronto-temporal lobe degeneration
GAA	Genetics Alliance (Australia)
GD	Gaucher disease
GRN: (CLN11)	<i>granulins</i>
GP	general practitioner
GROD	granular osmiophilic deposits
GTIC	genetic testing in children
HGSA	Human Genetic Society of Australasia
HMRI	Hunter Medical Research Institute
HREC	Human Research Ethics Committee
ICV	Intracerebroventricular
ID	identification code
IEMs	inborn errors of metabolism
INCL	infantile neuronal ceroid lipofuscinosis
IQR	interquartile range
IVF	in-vitro fertilisation
JNCL	juvenile neuronal ceroid lipofuscinosis
LD Australia	Lysosomal Diseases Australia
LD NZ	Lysosomal Diseases New Zealand
LINCL	late infantile neuronal ceroid lipofuscinosis
LOTE	language other than English

LSD	lysosomal storage disorder
MD	macular degeneration
M-L scale	motor-language scale
MPS	Mucopolysaccharidosis
MRI	magnetic resonance imaging
MST	mass spectrum technology
MAE	myoclonic astatic epilepsy
NCATS	National Centre for Advancing Translational Health
NHMRC	National Health and Medical Research Council
NIP	National Immunisation Program
NIH	National Institutes of Health
NCL	Neuronal Ceroid Lipofuscinosis
NCLs	Neuronal Ceroid Lipofuscinoses
NSW	New South Wales
OIS	organisation information statement
OMIM	Online Mendelian Inheritance in Man
PD	Parkinson's disease
PBAC	Pharmaceutical Benefits Advisory Committee
PGD	pre-implantation genetic diagnosis
pH	potential for Hydrogen
PIND	progressive intellectual and neurological deterioration
PIS	participant information statement
PKU	Phenylketonuria
PME	progressive myoclonus epilepsies
PPT1	Palmitoyl-protein thioesterase 1
REA	research ethics advisor
REM	rapid eye movement
REDCap®	Research Electronic Data Capture
RIMS	Research Information Management System
RP	retinitis pigmentosa
STROBE	Strengthening the Reporting of Observational Studies in Epidemiology
TPP1	Tripeptidyl peptidase 1
UK	United Kingdom
UoN	University of Newcastle, Australia
US	United States

## Definitions

adult	a person older than 18 years of age
Adult NCL	an adult-onset phenotype or genotype of NCL with an onset in early adulthood
child	reference to infants and children until the age of 18 years
classic	historical reference to original four NCL subtype groups: infantile, late-infantile, juvenile, adult
clinicopathological	a historical NCL diagnosis based on clinical presentation supported by pathology
Congenital NCL	usually CLN10 disease that is evident at birth or shortly afterwards but may have a later phenotype
diagnosis	estimated identification of a disease or condition based on clinical signs and symptoms, pathological, background, history, ultrastructural, and radiological findings
differential diagnosis	the process of differentiating between two or more conditions or diseases that may share a similar presentation of signs and symptoms
dysmorphia	subtle or distinct facial abnormalities that may be evident at birth or evolve
genotype	the mutations that make up the genetic makeup of an individual
heterogeneity	when the genetic mutation contains two different alleles of a gene
homogeneity	when the genetic mutation contains the two same alleles of a gene
hyposmia	a reduction in the sense of smell
incomplete diagnosis	a correct diagnosis such as epilepsy, which is not incorrect per se, but it is not the entire problem or disease that is emerging
infant:	from the post-natal period until the first twelve months of life
Infantile NCL	historical designation of this subtype commencing during infancy (referred to CLN1 if a genetic diagnosis is confirmed)
Juvenile NCL	historical designation of this subtype that began in middle childhood through the teens (referred to CLN3 if a genetic diagnosis is confirmed)
Late-infantile NCL	historical designation of this subtype that commenced during early childhood (now referred to CLN2 if a genetic diagnosis is confirmed)
nyctalopia	difficulty adapting or seeing in a dimly lit environment or at night
macrographia	progressively larger handwriting
micrographia	progressively smaller handwriting
neonate	newborn child, usually less than four weeks old
organomegaly	an enlarged organ such as engorged liver associated with a distended abdomen
pathognomonic	refers to signs, symptoms or investigation results which are characteristic or indicative of a particular disease or condition
phenoconversion	the interval during that the signs and symptoms present and become evident
phenotype	the disease presentation
polysomnography	sleep study
prenatal	prior to birth
sign	a tangible and overt indicator of a disease or condition
symptom	a subjective physical or psychological experience that is a precursor or concurrently occurring with the onset of a disease or condition
misdiagnosis	an incorrect diagnosis
missed diagnosis	a condition or disease that was overlooked at the time of presentation
teen	a child aged from ten years until 18 years of age
variant	reference to additional disease types such as the late-infantile variant: CLN5

# Contents

Statement of originality .....	ii
Acknowledgements.....	iii
Abbreviations.....	iv
Definitions .....	vi
Abstract .....	xiv
Chapter 1. Introduction .....	1
1.1 Overview .....	1
1.2.1 Emerging treatments for children diagnosed with NCL .....	3
1.2.2 Delayed diagnosis of NCL.....	3
1.2.3 Rare diseases in Australia.....	4
1.2.4 Epidemiology of NCL.....	5
1.3.1 Conceptual basis of the study .....	6
1.3.2 Theoretical background of the study.....	6
1.3.3 Problem statement.....	7
1.3.4 Literature gap .....	7
1.3.5 Justification of this study.....	8
1.3.6 Research questions .....	8
1.3.7 Aims of the study .....	9
1.3.8 Research design .....	9
1.3.9 Methodology summary .....	10
1.4 Structure of the thesis .....	10
1.5 Natural history study .....	10
1.6 Relevance of this study .....	11
1.7 Overview summary .....	13
1.8 Summary of NCL .....	13
Chapter 2. Literature Review.....	14
2.1 Introduction .....	14
2.1.1 Search strategy .....	15
2.1.2 Childhood and adult-onset NCL disease.....	16
2.1.3 Australian context.....	17
2.1.4 Introduction and literature search summary.....	18
2.2 Historical background NCL.....	18
2.2.1 Identification of the first <i>CLN</i> gene .....	19
2.2.2 Historical background summary .....	20
2.3 Literature review.....	20
2.4 NCL or Batten disease .....	22
2.5 Distinguishing features of NCL.....	24
2.5.1 Inborn Errors of Metabolism (IEMs) .....	25
2.5.2 Lysosomal Storage Disorders (LSDs) .....	26
2.5.3 Heterogeneity of NCL .....	26
2.5.4 Soluble enzyme deficiencies or transmembrane lysosomal defects .....	27
2.5.5 Multiple eponyms and names of NCL .....	27
2.5.6 Pathological features of NCL.....	28
2.5.7 Lipofuscin .....	29
2.5.8 Autofluorescence .....	29
2.5.9 Histopathology .....	29
2.5.10 Ultrastructural inclusions.....	31
2.5.11 Extra-neural pathology .....	32
2.5.12 Summary of distinguishing features of NCL.....	33
2.6 Early presentation of NCL.....	33
2.6.1 Epidemiology: Incidence and prevalence of NCL.....	34
2.6.2 NCL disease types .....	35
2.6.3 Background: Normal developmental milestones .....	36
2.6.4 Lack of clinically evident pathognomonic features.....	37
2.6.5 Early childhood .....	38
2.6.6 Disease features: Early signs and symptoms of NCL .....	38
2.6.7 Ages of onset.....	39
2.6.8 Dementia in childhood.....	40
2.6.9 Clinical heterogeneity of siblings.....	40

2.6.10 Gender differences .....	41
2.6.11 Additional considerations: Early-onset dementia in adults .....	41
2.6.12 Cardiac pathology .....	42
2.6.13 Late symptoms associated with a delayed diagnosis of CLN3.....	42
2.6.14 Late visual symptoms in CLN3 .....	43
2.6.15 Psychiatric symptoms in CLN3 .....	44
2.6.16 Summary of early presentation of NCL onset in children and adults .....	44
2.7 Diagnostic path of NCL .....	45
2.7.1 Disease onset, diagnosis, and treatment of NCL .....	46
2.8 Disease onset of NCL in childhood .....	47
2.8.1 Childhood natural history NCL studies .....	47
2.8.2 Parents' search for answers of new signs and symptoms .....	49
2.8.3 Educators' role prior to diagnosis.....	49
2.8.4 A potential prodromal phase in early NCL .....	49
2.8.6 Ataxia.....	51
2.8.7 Other pre-diagnostic symptoms of children .....	51
2.8.8 Health professionals' review before diagnosis of NCL .....	52
2.8.9 Speech pathologists .....	52
2.8.10 Ophthalmologists.....	53
2.8.11 Psychiatrists .....	53
2.8.12 Early childhood screening .....	54
2.8.13 Increased awareness of NCL .....	54
2.9 Diagnosis of NCL disease .....	55
2.9.1 Cell models and animal studies.....	55
2.9.2 Need for NCL biomarkers .....	55
2.9.3 Biomarker development .....	56
2.9.4 Nomenclature of NCL .....	56
2.9.5 Genetic links of NCL with adult neurodegenerative diseases .....	57
2.9.6 Diagnostic testing of NCL .....	59
2.9.7 Centres of 'Excellence' .....	60
2.9.8 Consanguinity .....	60
2.9.9 Genetic counselling .....	61
2.9.10 Pre-natal screening.....	61
2.9.11 Sibling diagnosis .....	62
2.9.12 Pre-symptomatic diagnosis of other children.....	63
2.9.13 Carrier testing of other children .....	64
2.9.14 Family experiences .....	65
2.9.15 Consequences of a delayed diagnosis .....	66
2.9.16 Differential diagnoses of NCL.....	68
2.9.17 Improved diagnostics of NCL .....	68
2.10 NCL Treatments .....	69
2.10.1 Clinical trials .....	69
2.10.2 Emerging treatments .....	69
2.10.3 Approved disease-modifying treatments .....	71
2.10.4 Role of supportive and palliative care for NCL .....	72
2.10.5 Summary of the NCL diagnostic path .....	73
2.11 What is the significance of this study? .....	74
2.12 Limitations of the literature review.....	76
2.13 Conclusion.....	76
2.14 Literature review summary .....	77
Chapter 3. Research design .....	78
3.1 Methods.....	78
3.1.1 Study design.....	78
3.1.2 Survey design.....	78
3.1.3 Research methods .....	79
3.1.4 Research paradigm.....	79
3.1.5 Pragmatic paradigm.....	79
3.1.6 Descriptive theory.....	80
3.1.7 Translational process .....	81
3.1.8 Philosophical stance of the student researcher .....	82



<b>3.1.9 Potential duality of the student researcher</b> .....	<b>83</b>
<b>3.1.10 Quantitative method</b> .....	<b>84</b>
<b>3.1.11 Free text contribution</b> .....	<b>85</b>
3.2 Setting .....	85
<b>3.2.1 On-line survey</b> .....	<b>85</b>
<b>3.2.2 Location</b> .....	<b>85</b>
<b>3.2.3 Periods of recruitment</b> .....	<b>86</b>
<b>3.2.4 Follow-up</b> .....	<b>86</b>
<b>3.2.5 Data collection</b> .....	<b>86</b>
<b>3.2.6 The consultative phase</b> .....	<b>86</b>
<b>3.2.7 The survey phase</b> .....	<b>86</b>
3.3 Participants.....	87
<b>3.3.1 Study population</b> .....	<b>87</b>
<b>3.3.2 Eligibility criteria</b> .....	<b>87</b>
3.4 Participant safety.....	88
<b>3.4.1 Confidentiality</b> .....	<b>88</b>
<b>3.4.2 Anonymity</b> .....	<b>89</b>
<b>3.4.3 Right of withdrawal from the survey phase</b> .....	<b>89</b>
<b>3.4.4 Potential benefits to participants</b> .....	<b>90</b>
<b>3.4.5 Potential risks to participants</b> .....	<b>90</b>
<b>3.4.6 Vulnerable population</b> .....	<b>90</b>
<b>3.4.7 Potential burden to participants</b> .....	<b>91</b>
3.5 Development of the cross-sectional survey .....	92
<b>3.5.1 Validated survey</b> .....	<b>92</b>
<b>3.5.2 Domains of the survey</b> .....	<b>92</b>
<b>3.5.3 Survey Monkey</b> .....	<b>92</b>
<b>3.5.4 REDCap® Survey</b> .....	<b>93</b>
<b>3.5.5 Question development</b> .....	<b>93</b>
<b>3.5.6 Part A survey</b> .....	<b>95</b>
<b>3.5.7 Part B survey</b> .....	<b>96</b>
<b>3.5.8 Linking multiple surveys</b> .....	<b>96</b>
<b>3.5.9 De-identifying participants</b> .....	<b>97</b>
<b>3.5.10 Child's ID code</b> .....	<b>97</b>
<b>3.5.11 Family ID code</b> .....	<b>98</b>
<b>3.5.12 Diagnostic time frames</b> .....	<b>98</b>
<b>3.5.13 Peer review of surveys</b> .....	<b>99</b>
3.6 The consultative phase .....	99
<b>3.6.1 Key informant role</b> .....	<b>100</b>
<b>3.6.2 Recruitment of key informants</b> .....	<b>101</b>
<b>3.6.3 Number of participants</b> .....	<b>101</b>
<b>3.6.4 Sub-populations of participants</b> .....	<b>101</b>
<b>3.6.5 Signed consent for the consultative phase</b> .....	<b>101</b>
<b>3.6.6 Confidentiality of the consultative phase participants</b> .....	<b>102</b>
<b>3.6.7 Right of withdrawal from the consultative phase</b> .....	<b>102</b>
<b>3.6.8 Preliminary viewing of surveys</b> .....	<b>102</b>
<b>3.6.9 Feedback of the survey</b> .....	<b>102</b>
<b>3.6.10 Variation to ethics</b> .....	<b>103</b>
3.7 The survey phase: Data collection .....	103
<b>3.7.1 Participant recruitment</b> .....	<b>103</b>
<b>3.7.2 Advertisement of the study</b> .....	<b>104</b>
<b>3.7.3 Organisation information statement and consent</b> .....	<b>105</b>
<b>3.7.4 The survey phase participant information statement (PIS)</b> .....	<b>105</b>
<b>3.7.5 Implied consent for on-line survey</b> .....	<b>106</b>
3.8 Sample .....	106
<b>3.8.1 Purposive sampling</b> .....	<b>106</b>
<b>3.8.2 Study population</b> .....	<b>107</b>
<b>3.8.3 Sub-populations</b> .....	<b>108</b>
<b>3.8.4 Minimum response rate</b> .....	<b>109</b>
<b>3.8.5 Duplicate surveys</b> .....	<b>111</b>
<b>3.8.6 Secondary recruitment</b> .....	<b>111</b>

3.9 Variables .....	112
<b>3.9.1 Primary and secondary outcomes .....</b>	<b>112</b>
<b>3.9.2 Diagnostic criteria .....</b>	<b>112</b>
3.10 Measurement .....	112
<b>3.10.1 Measurement for each variable of interest .....</b>	<b>112</b>
<b>3.10.2 Comparability of assessment methods for more than one group .....</b>	<b>112</b>
3.11 Bias .....	113
<b>3.11.1 Efforts to address potential sources of bias .....</b>	<b>113</b>
<b>3.11.2 Impact of study size .....</b>	<b>114</b>
3.12 Study size .....	115
<b>3.12.1 Deriving the study size .....</b>	<b>115</b>
3.13 Analysis .....	115
<b>3.13.1 Statistical Analysis .....</b>	<b>115</b>
<b>3.13.2 Cohort characteristics .....</b>	<b>116</b>
<b>3.13.3 Groupings selected for this study .....</b>	<b>116</b>
3.14 Subcategories of data .....	116
<b>3.14.1 Descriptive and outcome data .....</b>	<b>116</b>
<b>3.14.2 Free text .....</b>	<b>117</b>
<b>3.14.3 How missing data were addressed .....</b>	<b>117</b>
<b>3.14.4 Database entry .....</b>	<b>117</b>
<b>3.14.5 Storage of data .....</b>	<b>117</b>
<b>3.14.6 Data protection .....</b>	<b>118</b>
3.15 Ethics .....	118
<b>3.15.1 Ethics application .....</b>	<b>118</b>
<b>3.15.2: New Zealand participants .....</b>	<b>118</b>
<b>Chapter 4: Results of the consultative phase .....</b>	<b>119</b>
<b>4.1.1 Key informants .....</b>	<b>119</b>
<b>4.1.2 Key informant response .....</b>	<b>119</b>
<b>4.1.3 Participant signed consent .....</b>	<b>119</b>
<b>4.1.4 Consultative phase participants .....</b>	<b>120</b>
<b>4.2 Feedback regarding the PIS .....</b>	<b>120</b>
<b>4.3.1 Draft NCL survey .....</b>	<b>120</b>
<b>4.3.2 Survey question five .....</b>	<b>120</b>
<b>4.3.3 Key informant feedback .....</b>	<b>121</b>
<b>4.4.1 CLN3 disease .....</b>	<b>123</b>
<b>4.4.2 CLN3 diagnosis .....</b>	<b>123</b>
<b>4.5.1 Delivery of diagnosis .....</b>	<b>125</b>
<b>4.5.2 Future qualitative research .....</b>	<b>125</b>
<b>4.6 Feedback of the Part B survey .....</b>	<b>126</b>
<b>4.7 Incomplete diagnoses .....</b>	<b>126</b>
<b>4.8.1 A bimodal onset of symptoms for CNL3 .....</b>	<b>126</b>
<b>4.8.2 A slowly evolving genotype such as CLN3 .....</b>	<b>127</b>
<b>4.9.1 Review of feedback by the research team .....</b>	<b>127</b>
<b>4.9.2 Additional question .....</b>	<b>128</b>
<b>4.10.1 Amendments to documents .....</b>	<b>128</b>
<b>4.10.2 Ethics variation after the consultative phase .....</b>	<b>129</b>
<b>4.10.3 Family ID code .....</b>	<b>130</b>
<b>4.11 Summary of the consultative phase results .....</b>	<b>130</b>
<b>Chapter 5: Results of the survey phase .....</b>	<b>132</b>
<b>5.1. Participants .....</b>	<b>132</b>
<b>5.1.1 Survey participants .....</b>	<b>132</b>
<b>5.1.2 Participants in the NCL survey (Part A) .....</b>	<b>133</b>
<b>5.1.3 Participants in the NCL survey (Part B) .....</b>	<b>133</b>
<b>5.1.4 Recruitment periods .....</b>	<b>133</b>
<b>5.1.5 A&amp;NZ participants: .....</b>	<b>134</b>
<b>5.1.6 Completeness of the data .....</b>	<b>134</b>
<b>5.2 Participant Demographics .....</b>	<b>135</b>
<b>5.2.1 Geographic location of participants .....</b>	<b>135</b>
<b>5.2.2 Aboriginal and/or Torres Strait Islander or Maori heritage .....</b>	<b>137</b>
<b>5.2.3 Ethnicity of parents .....</b>	<b>137</b>

5.2.4 Ethnicity of grandparents.....	137
5.2.5 NCL disease types in A&NZ children.....	139
5.2.6 Gene characteristics of the index cases of the A&NZ NCL cohort.....	139
5.3 Primary outcome of the study: diagnostic timeline.....	140
5.3.1 Diagnostic delay.....	140
5.3.2 Comparisons of the CLN2 and CLN3 subgroups .....	141
5.3.3 Estimates of Time to Disease Diagnosis .....	142
5.4 Secondary outcome .....	144
5.4.1 Investigations timeline .....	144
5.5 First signs and symptoms of childhood NCL.....	145
5.5.1 First signs and symptoms of combined NCL disease types.....	145
5.5.2 First signs and symptoms of the individual NCL disease types.....	146
5.5.3 Ages of onset of individual NCL diseases .....	151
5.6 The first person to notice initial signs and symptoms .....	152
5.6.1 The individual who first prompted medical investigation of a child.....	154
5.6.2 First types of tests undertaken before NCL diagnosis in A&NZ children .....	155
5.6.3 Secondary tests undertaken before a NCL diagnosis in A&NZ cohort .....	156
5.6.4 Types of confirmatory diagnostic tests of NCL disease each decade .....	157
5.7 Differential diagnoses.....	158
5.7.1 Conditions or diseases associated with the diagnosis of NCL .....	158
5.7.2 Differential diagnoses initially provided before a NCL diagnosis .....	159
5.7.3 Year of diagnosis .....	159
5.7.4 Comparative analysis between the A&NZ CLN3 subgroups .....	160
5.7.5 The provision of their child’s NCL diagnosis to parents .....	161
5.8 Supports and social media (domain 5) .....	161
5.8.1 Role of BDSRA Australia, internet, and social media .....	161
5.8.2 Prior awareness of Batten disease.....	162
5.8.3 Participation in a NCL patient registry.....	163
5.8.4 Diagnosis of another disease or condition concurrent with NCL.....	163
5.9 Collation of free text provided by participants .....	163
5.9.1 Additional free text in Part A of the survey .....	163
5.9.2 Additional free text provided in Part B of the survey .....	165
5.9.3 Case report of a child’s CLN2 diagnosis .....	167
5.10 Results of NCL Survey (Part B) .....	168
5.10.1 Carrier genetic testing of other children (‘sibs’ of affected children) .....	170
5.10.2 Carrier genetic testing of parents.....	170
5.10.3 Pre-symptomatic testing of other at-risk other children.....	170
5.10.4 Decade genetic testing was undertaken.....	171
5.10.5 Genetic counselling.....	171
5.11 Hindrances and facilitators of NCL diagnosis .....	171
5.12 Summation .....	173
<b>Chapter 6: Discussion .....</b>	<b>176</b>
6.1 Conclusion.....	212
<b>7. References .....</b>	<b>215</b>
<b>8. Appendices .....</b>	<b>244</b>
Appendix 1 .....	244
Study design.....	244
Appendix 2 .....	245
Thesis timeline .....	245
Appendix 3 .....	246
Study budget .....	246
Appendix 4 .....	247
Preliminary tests for NCL subtypes Part A and B Tables and references .....	247
Appendix 5.....	253
Diagnostic algorithm for NCL subtypes .....	253
Appendix 6.....	254
NCL Survey domains .....	254
Appendix 7 .....	255
Letter for the consultative phase (Phase 1) key informants.....	255
Appendix 8 .....	257

The consultative phase (Phase 1) participant information statement .....	257
Appendix 9 .....	260
The consultative phase consent form.....	260
Appendix 10 .....	261
NCL survey phase (Phase 2) participant information statement .....	261
Appendix 11 .....	264
NCL survey: pages 1 - 19 .....	264
Appendix 12 .....	283
Letter of request for organisations (BDSRA) to advertise the study.....	283
Appendix 13 .....	285
Organisation information statement .....	285
Appendix 14 .....	287
Organisation consent .....	287
Appendix 15 .....	288
Survey flyer .....	288
Appendix 16 .....	289
Early signs and symptoms of NCL poster 'NEURONS' model .....	289
Appendix 17 .....	290
Table 23: Hindrances and facilitators of NCL diagnosis in children .....	290

### List of Tables

Table 1: Methodology summary .....	10
Table 2: Search terms used for the literature search .....	16
Table 3: Historical and recent eponyms and synonyms of NCL diseases .....	21
Table 4: Genetic spectrum and new nomenclature of NCL diseases .....	36
Table 5: Earliest onset age of classic and variant CLN1 - CLN14 diseases.....	40
Table 6: Study sub-populations.....	108
Table 7: Sub-categories of the data .....	117
Table 8: Amendments to the survey phase PIS and NCL survey.....	129
Table 9: Gene classification of the A&NZ study cohort of index cases.....	139
Table 10: Primary outcome of the NCL diagnostic delay in 26 A&NZ children.....	140
Table 11: Median diagnostic timeline of the CLN2 and CLN3 gene subgroups .....	141
Table 12: Secondary outcome of the survey phase of A&NZ NCL cohort.....	144
Table 13: Parental report of first signs and symptoms of each NCL disease type .....	150
Table 14: Diagnostic confirmation of each NCL disease in consecutive decades.....	158
Table 15: Diagnoses provided before or concurrently with the NCL diagnosis .....	158
Table 16: Differential diagnoses provided before a NCL diagnosis .....	159
Table 17: Australian (median index cases) and New Zealand CLN3 diagnosis .....	161
Table 18: How and where the diagnosis of NCL was provided to parents .....	161
Table 19: Supports and social media .....	162
Table 20: Summary of free text content provided by parents in Part A of the survey.....	164
Table 21: Collation of free text provided by participants in Part B of the survey .....	166
Table 22: Part B survey responses to family carrier and predictive genetic testing .....	169
Table 23: Hindrances and facilitators of NCL diagnosis in children.....	290

## List of Figures

Figure 1: Barriers in rare disease diagnosis.....	6
Figure 2: Three main themes of diagnosis of childhood-onset NCL diseases.....	24
Figure 3: Subgroups of the metabolic disorders .....	25
Figure 4: Vacuoles in lymphocyte cytoplasm of an individual with CLN3 disease.....	31
Figure 5: Features of the early presentation of childhood-onset NCL diseases .....	34
Figure 6: Factors impacting the disease onset, diagnosis, and treatment of NCL .....	47
Figure 7: Direct genetic links of NCL with other rare or more common diseases .....	59
Figure 8: Emerging NCL treatments.....	71
Figure 9 : Theoretical basis and paradigm of research.....	80
Figure 10: Translational rare diseases diagnostic roadmap .....	82
Figure 11: Child's ID code .....	98
Figure 12: Genetic inheritance of Batten disease or NCL.....	109
Figure 13: Number of A&NZ children included in data analysis of survey phase .....	133
Figure 14: Remote rural, town, or city locale of Australian residents at diagnosis .....	135
Figure 15: State and territories of Australian residents where children diagnosed.....	136
Figure 16a & 16b: Country of birth - maternal and paternal A&NZ grandparents.....	138
Figure 17: NCL diseases CLN1 - CLN3 and CLN5 in this cohort of A&NZ children.....	139
Figure 18: Diagnostic timeline of combined NCL disease types, CLN2, and CLN3 .....	141
Figure 19: Kaplan-Meier plot: Time to diagnosis including number at risk .....	143
Figure 20: Kaplan-Meier plot: Time to diagnosis for CLN2 and CLN3 subgroups.....	144
Figure 21: First signs and/or symptoms identified in this A&NZ childhood cohort.....	145
Figure 22a & 22b: First signs and/or symptoms of CLN1 in Australian children.....	147
Figure 23: First signs and/or symptoms of CLN2 in Australian children .....	147
Figure 24: First signs and/or symptoms of CLN3 in A&NZ children.....	148
Figure 25a & 25b: First signs and/or symptoms of CLN5 in the A&NZ cohort.....	149
Figure 26: Range of age onset of signs &/or symptoms in CLN1 - CLN3 diseases .....	151
Figure 27: Range of age onset of signs and/or symptoms in children with CLN5 .....	152
Figure 28: Individuals who identified the first signs and symptoms in A&NZ cohort.....	152
Figure 29: Individuals who prompted the first investigations of a symptomatic child.....	155
Figure 30: First investigations of these A&NZ children before a NCL diagnosis .....	156
Figure 31: Secondary tests undertaken before a NCL diagnosis in A&NZ cohort.....	157
Figure 32: Demi-decade of NCL diagnosis type of A&NZ children .....	160
Figure 33: The decade/s parents considered undertaking genetic testing .....	171
Figure 34: Facilitators of childhood-onset NCL diagnosis.....	172
Figure 35: The broad facilitators and hindrances of NCL diagnosis in children.....	173
Figure 36: Potential prodromal signs of NCL onset in children .....	194
Figure 37: 'NEURONS' first signs or symptoms of childhood-onset NCL diseases .....	195
Figure 38: Different sequence of the 'NEURONS' model based on NCL disease.....	200

## Abstract

Neuronal Ceroid Lipofuscinosis (NCL) or Batten disease, is a group of predominantly recessively-inherited neurodegenerative diseases that mostly affect children. It is the most common genetic cause of dementia in children, yet a rare cause of dementia in adults. Although NCL remains life-limiting, clinical trials are in development for specific disease types. NCL has a low Australian and New Zealand incidence, but a devastating impact on affected children and their families. Currently, neither country participates in an international NCL patient registry that leaves these families isolated from potential research and therapeutic agents. As recently as 2017, a historical milestone was passed with the approval of the first disease-modifying enzyme replacement therapy - Brineura® for ceroid lipofuscinosis, neuronal 2 or CLN2.

Research has consistently identified a protracted diagnostic period of NCL. Retrospectively identifying the earliest onset of the disease could feasibly impact future diagnostic delays. Subtle early signs and symptoms merge with other rare or common diseases and can be missed. This study describes the early phase of NCL in this cohort of A&NZ children. It uses parent-report to retrospectively identify the earliest sign or symptom that led to the diagnosis or that should have led to the diagnosis with hindsight. To achieve this aim, the parents' experiences, and any facilitators of a timely diagnosis of NCL were also explored.

Databases including PubMed and manual searches of reference lists provided a comprehensive historical and contemporary literature review, focused on the onset of NCL. Specific research of the initial presentation of NCL during childhood was limited; however, themes of early signs and symptoms were identified. Corresponding with the literature, the mnemonic 'NEURONS' was devised by the student researcher to incorporate the early signs and symptoms of childhood-onset NCL diseases. These include **N**eurological stalling and/or **E**pilepsy. **U**ltrastructural features are distinctive but not unique to each disease. **R**egression of milestones and abilities become evident. **O**phthalmic signs with visual loss behaviour and vacuolated lymphocytes are associated with CLN3. **N**ew-onset ataxia and early **S**peech delays are aligned with specific diseases such as CLN2.

After gaining University of Newcastle Human Research Ethics Committee approval [No. H-2018-0059], a purposive sample was obtained. Participation was offered to all A&NZ parents/legal guardians of children, alive or deceased, diagnosed with any NCL disease in the past five decades. Recruitment was initiated through the Australian chapter of the Batten Disease Research Association (BDSRA) family support group, two alternate organisations, and snowball recruitment. There were two phases of the study: The consultative phase comprised of key informant consultation in the design of the quantitative survey regarding children with an NCL diagnosis. The survey phase incorporated a structured cross-sectional survey devised by the research team. Potential participants were invited to complete the REDCap® on-line survey, using links on the Australian BDSRA Facebook® page or website. The anonymous survey asked parents to retrospectively explore the diagnosis of their child's disease in a chronological format, with an option to provide additional text.

Facilitators and hindrances of childhood-onset NCL diagnosis were identified. Pre-genetic clinical, enzymatic, and/or genetic diagnoses were categorised. There were 29 A&NZ parent participants of children with either CLN1, CLN2, CLN3, or CLN5 disease. Predominantly, the parents identified the earliest changes and prompted investigation of their child. Initial misdiagnoses included up to four alternate diagnoses. The primary outcome of the study identified a two-year median diagnostic delay, including a one-year delay before investigations were initiated. A cohort of 26 children of index cases with a confirmed age of onset, did not include two facilitated pre-symptomatic diagnoses.

The diagnostic 'odyssey' discussed in the rare disease literature, was similarly identified in this A&NZ study. The longest delay determined in this study was a recent protracted diagnosis of nine years and nine months for a child with CLN3. Early signs and symptoms were aligned with the NEURONS model based on the literature. Speech pathologists or ophthalmologists reviewed these children with either speech delays and/or loss or a new onset visual loss, associated with the early sign of clumsiness. Education programmes may increase specific health professionals' awareness of NCL, reduce future diagnostic delays for NCL, and improve family access to emerging clinical trials and available treatments.